Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 41Leukemia 34Lymphoma 22Myelodysplastic Syndromes 16Hodgkin Disease 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Multiple Myeloma 10Lymphoma, Non-Hodgkin 10Lymphoma, Mantle-Cell 9Leukemia, Myeloid, Acute 9Recurrence 8Myeloproliferative Disorders 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Myeloid, Chronic-Phase 7Anemia, Aplastic 7Waldenstrom Macroglobulinemia 6Lymphoma, T-Cell, Peripheral 6Congenital Abnormalities 6Burkitt Lymphoma 6Sezary Syndrome 5Primary Myelofibrosis 5Neoplasms, Plasma Cell 5Mycosis Fungoides 5Lymphoma, Large-Cell, Immunoblastic 5Graft vs Host Disease 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, T-Cell, Cutaneous 4

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Alemtuzumab × Clear all
NCT00895739 2013-08-12

Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure

National Cancer Institute (NCI)

Phase 2 Unknown
50 enrolled
Classical hematology

Anemia, Aplastic, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡